{"groups":[{"description":"Participants in Cohort 1 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"FG000","title":"Cohort 1 - Safety Lead-in (TTX-030 + Budigalimab + mFOLFOX6)"},{"description":"Participants in Cohort 3B were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"FG001","title":"Cohort 3B - Gastric (TTX-030 + Budigalimab + mFOLFOX6)"},{"description":"Participants in Cohort 12 were administered IV budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"FG002","title":"Cohort 12 - Gastric (Budigalimab + mFOLFOX6)"},{"description":"Participants in Cohort 3A were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"FG003","title":"Cohort 3A - Gastric (TTX-030 + mFOLFOX6)"},{"description":"Participants in Safety Lead-in Cohort 2 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab 375 mg Q3W plus docetaxel at a dose of 75 mg/m2 Q3W on Day 1 of each 21-day treatment cycle.","id":"FG004","title":"Cohort 2 - mCRPC (TTX-030 + Budigalimab + Docetaxel)"},{"description":"Participants in Cohort 9 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.","id":"FG005","title":"Cohort 9 - Pancreatic (TTX-030 + Budigalimab + Gemcitabine + Nab-Paclitaxel)"},{"description":"Participants in Cohort 11 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.","id":"FG006","title":"Cohort 11 - Pancreatic (TTX-030 + Gemcitabine + Nab-Paclitaxel)"},{"description":"Participants in Cohort 4 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"FG007","title":"Cohort 4 - CRC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 6 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"FG008","title":"Cohort 6 - HNSCC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 8 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"FG009","title":"Cohort 8 - GEC (TTX-030 + Budigalimab)"},{"description":"Participants in Cohort 10 were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus pembrolizumab at a dose of 200 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"FG010","title":"Cohort 10 - UCC (TTX-030 + Pembrolizumab)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"44"},{"groupId":"FG002","numSubjects":"25"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"28"},{"groupId":"FG006","numSubjects":"17"},{"groupId":"FG007","numSubjects":"14"},{"groupId":"FG008","numSubjects":"5"},{"groupId":"FG009","numSubjects":"23"},{"groupId":"FG010","numSubjects":"8"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"44"},{"groupId":"FG002","numSubjects":"25"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"28"},{"groupId":"FG006","numSubjects":"17"},{"groupId":"FG007","numSubjects":"14"},{"groupId":"FG008","numSubjects":"5"},{"groupId":"FG009","numSubjects":"23"},{"groupId":"FG010","numSubjects":"8"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}